Monica Holmberg, PharmD, BCPS

FDA approves a new liquid formulation of losartan for hypertension treatment, enhancing accessibility for adults and children over 6 years old.

The FDA recently approved gepotidacin oral tablets for the treatment of uncomplicated urinary tract infections (UTIs).

Suzetrigine, a new nonopioid pain reliever, gains FDA approval for treating moderate to severe acute pain in adults, offering a safer alternative to opioids.

The approval carries the limitation that ritlecitinib should not be used in combination with biologic immunomodulators, cyclosporine, other Janus kinase inhibitors, or other potent immunosuppressants.

The approval carries the limitation that bexagliflozin may increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.

Leqembi is an intravenous injection for the treatment of Alzheimer disease.

Adagrasib is a RAS GTPase family inhibitor with objective response rate in patients with certain types of locally advanced or metastatic non–small cell lung cancer (NSCLC).

Tzield does not have any known contraindications.

Eflapegrastim-xnst subcutaneous injection (Rolvedon) reduces infections related to febrile neutropenia in adults with nonmyeloid malignant tumors who are being treated with certain anticancer drugs.

The drug is indicated for moderate to severe plaque psoriasis.

The FDA approved a new azole antifungal for recurrent vulvovaginal candidiasis.